MedTrace Logo

Molecular Subtyping of Extensive Stage Small Cell Lung Cancer and Relevent Clinical Significance

NCT05933863 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 168

Last updated 2024-12-16

No results posted yet for this study

Summary

To validate the predictive value of transcriptome-based molecular subtyping of extensive stage small cell lung cancer (SCLC) for the efficacy of programmed death-1(PD-1)/programmed death-ligand1(PD-L1) inhibitor in the first line setting; to explore the differences of immune microenvironment between different SCLC subtypes to reveal the mechanisms of immunotherapy resistance of SCLC

Conditions

  • SCLC,Extensive Stage

Interventions

DRUG

PD-(L)1 antibody immunotherapy

The treatment regimen involved in this study follows guidelines for the first-line treatment of extensive stage SCLC: cisplatin+etoposide or carboplatin+etoposide and PD-(L)1 inhibitor.

Sponsors & Collaborators

  • Peking University Cancer Hospital & Institute

    lead OTHER

Principal Investigators

  • Minglei Zhuo, Physician · Peking University Cancer Hospital & Institute

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-29
Primary Completion
2024-07-18
Completion
2024-12-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05933863 on ClinicalTrials.gov